ArticleBlood cancer discovery2024

Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor-Adoptive T-cell Therapy.

George Mo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.